Frances Jenkins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Frances Jenkins has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Sebastiaan J. van Hal
New South Wales Health Pathology, Microbiology, Royal Prince Alfred Hospital
3 shared publications Rima Farhat
2 shared publications- Angie Natalie Pinto
Department of Infectious Diseases, Woodlands Hospital, Singapore, Singapore
1 shared publication Angie Pinto
Department of Infectious Diseases and Microbiology Royal Prince Alfred Hospital Sydney Australia
1 shared publication- Anurag Adhikari
Department of Infection and Immunology, Kathmandu Research Institute for Biological Sciences, Lalitpur, Nepal
1 shared publication Azim Anzari
Wellcome Centre for Human Genetics University of Oxford Oxford UK
1 shared publication
Latest Publications
- Open Access
- 5 December 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (12) , e29273
Validation of an HIV whole genome sequencing method for HIV drug resistance testing in an Australian clinical microbiology laboratory
Detection of HIV drug resistance (HIVDR) is vital to successful anti‐retroviral therapy (ART). HIVDR testing to determine drug‐resistance mutations is routinely performed in Australia to guide ART choice in newly diagnosed people living with HIV or in cases of treatment failure. In 2022, our clinical microbiology laboratory sought to validate a next‐generation sequencing (NGS)‐based HIVDR assay to replace the previous Sanger‐sequencing (SS)‐based ViroSeq. NGS solutions for HIVDR offer higher throughput, lower costs and higher sensitivity for variant detection. We sought to validate the previously described low‐cost probe‐based NGS method (veSEQ‐HIV) for whole‐genome recovery and HIVDR‐testing in a diagnostic setting. veSEQ‐HIV displayed 100% and 98% accuracy in major and minor mutation detection, respectively, and 100% accuracy of subtyping (provided > 1000 mapped reads were obtained). Pairwise comparison exhibited low inter‐and intrarun variability across the whole‐genome (Jaccard index [J] = 0.993; J = 0.972) and the Pol gene (J = 0.999; J = 0.999), respectively. veSEQ‐HIV met all our pre‐set criteria based on WHO recommendations and successfully replaced ViroSeq in our laboratory. Scaling‐down veSEQ‐HIV to a limited batch size and sequencing on Illumina iSeq. 100, allowed easy implementation of the assay into the workflow of a small sequencing laboratory with minimal staff and equipment and the ability to meet clinically relevant test turn‐around times. As HIVDR‐testing moves from SS‐ to NGS‐based methods and new ART drugs come to market (particularly those with targets outside the Pol region), whole‐genome recovery using veSEQ‐HIV provides a robust, cost‐effective and “future‐proof” NGS method for HIVDR‐testing.
- 5 December 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (12) , e29273
Open AccessValidation of an HIV whole genome sequencing method for HIV drug resistance testing in an Australian clinical microbiology laboratory
Detection of HIV drug resistance (HIVDR) is vital to successful anti‐retroviral therapy (ART). HIVDR testing to determine drug‐resistance mutations is routinely performed in Australia to guide ART choice in newly diagnosed people living with HIV or in cases of treatment failure. In 2022, our clinical microbiology laboratory sought to validate a next‐generation sequencing (NGS)‐based HIVDR assay to replace the previous Sanger‐sequencing (SS)‐based ViroSeq. NGS solutions for HIVDR offer higher throughput, lower costs and higher sensitivity for variant detection. We sought to validate the previously described low‐cost probe‐based NGS method (veSEQ‐HIV) for whole‐genome recovery and HIVDR‐testing in a diagnostic setting. veSEQ‐HIV displayed 100% and 98% accuracy in major and minor mutation detection, respectively, and 100% accuracy of subtyping (provided > 1000 mapped reads were obtained). Pairwise comparison exhibited low inter‐and intrarun variability across the whole‐genome (Jaccard index [J] = 0.993; J = 0.972) and the Pol gene (J = 0.999; J = 0.999), respectively. veSEQ‐HIV met all our pre‐set criteria based on WHO recommendations and successfully replaced ViroSeq in our laboratory. Scaling‐down veSEQ‐HIV to a limited batch size and sequencing on Illumina iSeq. 100, allowed easy implementation of the assay into the workflow of a small sequencing laboratory with minimal staff and equipment and the ability to meet clinically relevant test turn‐around times. As HIVDR‐testing moves from SS‐ to NGS‐based methods and new ART drugs come to market (particularly those with targets outside the Pol region), whole‐genome recovery using veSEQ‐HIV provides a robust, cost‐effective and “future‐proof” NGS method for HIVDR‐testing.
- Open Access
- 14 May 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (9) , 4043-4046
Persistent high‐level shedding of cultivable SARS‐CoV‐2 Delta virus 33 days after onset of COVID‐19 in a hospitalized patient with pneumonia
- 14 May 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (9) , 4043-4046
Open AccessPersistent high‐level shedding of cultivable SARS‐CoV‐2 Delta virus 33 days after onset of COVID‐19 in a hospitalized patient with pneumonia